Birchview Capital as of June 30, 2024
Portfolio Holdings for Birchview Capital
Birchview Capital holds 60 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 26.5 | $29M | 688k | 41.53 | |
| Biodesix (BDSX) | 7.9 | $8.5M | 5.5M | 1.53 | |
| Aziyo Biologics (ELUT) | 7.1 | $7.7M | 1.6M | 4.96 | |
| Neurocrine Biosciences (NBIX) | 5.4 | $5.8M | 42k | 137.67 | |
| Silk Road Medical Inc Common | 4.0 | $4.3M | 158k | 27.04 | |
| Prothena Corp SHS (PRTA) | 3.9 | $4.2M | 204k | 20.64 | |
| ACADIA Pharmaceuticals (ACAD) | 3.8 | $4.1M | 250k | 16.25 | |
| Encana Corporation (OVV) | 3.2 | $3.5M | 74k | 46.87 | |
| United Therapeutics Corporation (UTHR) | 3.0 | $3.2M | 10k | 318.55 | |
| Harrow Health (HROW) | 2.9 | $3.1M | 150k | 20.89 | |
| Stoke Therapeutics (STOK) | 2.6 | $2.8M | 210k | 13.51 | |
| Phreesia (PHR) | 2.3 | $2.4M | 115k | 21.20 | |
| Corcept Therapeutics Incorporated (CORT) | 2.2 | $2.4M | 74k | 32.49 | |
| Quidel Corporation | 2.1 | $2.2M | 68k | 33.22 | |
| Masimo Corporation (MASI) | 1.8 | $1.9M | 15k | 125.94 | |
| Foghorn Therapeutics (FHTX) | 1.7 | $1.8M | 321k | 5.75 | |
| Equitrans Midstream Corp (ETRN) | 1.6 | $1.7M | 133k | 12.98 | |
| Protagonist Therapeutics (PTGX) | 1.5 | $1.7M | 48k | 34.65 | |
| Axogen (AXGN) | 1.3 | $1.4M | 197k | 7.24 | |
| Docgo (DCGO) | 1.3 | $1.4M | 460k | 3.09 | |
| Alkermes SHS (ALKS) | 1.1 | $1.2M | 50k | 24.10 | |
| Travere Therapeutics (TVTX) | 0.9 | $1.0M | 122k | 8.22 | |
| Alphatec Holdings (ATEC) | 0.9 | $920k | 88k | 10.45 | |
| Castle Biosciences (CSTL) | 0.7 | $740k | 34k | 21.77 | |
| Exxon Mobil Corporation (XOM) | 0.6 | $673k | 5.8k | 115.12 | |
| Progyny (PGNY) | 0.6 | $629k | 22k | 28.61 | |
| 10x Genomics Cl A Com (TXG) | 0.5 | $584k | 30k | 19.45 | |
| Kiniksa Pharmaceuticals | 0.5 | $560k | 30k | 18.67 | |
| Kalvista Pharmaceuticals (KALV) | 0.5 | $542k | 46k | 11.78 | |
| Cytokinetics (CYTK) | 0.5 | $542k | 10k | 54.18 | |
| Apellis Pharmaceuticals (APLS) | 0.5 | $537k | 14k | 38.36 | |
| Halozyme Therapeutics (HALO) | 0.5 | $524k | 10k | 52.36 | |
| Coherus Biosciences (CHRS) | 0.4 | $467k | 270k | 1.73 | |
| Karyopharm Therapeutics | 0.4 | $408k | 470k | 0.87 | |
| Arvinas Ord (ARVN) | 0.4 | $399k | 15k | 26.62 | |
| Sarepta Therapeutics (SRPT) | 0.4 | $395k | 2.5k | 158.00 | |
| Xenon Pharmaceuticals (XENE) | 0.4 | $390k | 10k | 38.99 | |
| Accelr8 Technology | 0.4 | $381k | 325k | 1.17 | |
| Springworks Therapeutics (SWTX) | 0.3 | $377k | 10k | 37.67 | |
| Cullinan Oncology (CGEM) | 0.3 | $349k | 20k | 17.44 | |
| Novocure Ord Shs (NVCR) | 0.3 | $343k | 20k | 17.13 | |
| Axsome Therapeutics (AXSM) | 0.3 | $322k | 4.0k | 80.50 | |
| Keros Therapeutics (KROS) | 0.3 | $320k | 7.0k | 45.70 | |
| Bluebird Bio | 0.3 | $306k | 311k | 0.98 | |
| Amicus Therapeutics (FOLD) | 0.3 | $278k | 28k | 9.92 | |
| Biohaven Pharmaceutical Holding | 0.2 | $256k | 7.4k | 34.71 | |
| BioCryst Pharmaceuticals (BCRX) | 0.2 | $247k | 40k | 6.18 | |
| Xencor (XNCR) | 0.2 | $233k | 12k | 18.93 | |
| Wave Life Sciences SHS (WVE) | 0.2 | $200k | 40k | 4.99 | |
| G1 Therapeutics | 0.2 | $182k | 80k | 2.28 | |
| Inhibrx Biosciences (INBX) | 0.2 | $171k | 12k | 14.09 | |
| Gossamer Bio (GOSS) | 0.1 | $125k | 138k | 0.90 | |
| Liquidia Technologies (LQDA) | 0.1 | $120k | 10k | 12.00 | |
| Inflarx Nv (IFRX) | 0.1 | $87k | 50k | 1.74 | |
| Cabaletta Bio (CABA) | 0.1 | $75k | 10k | 7.48 | |
| 2seventy Bio | 0.1 | $69k | 18k | 3.85 | |
| Ventyx Biosciences (VTYX) | 0.1 | $67k | 29k | 2.31 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $65k | 16k | 4.09 | |
| Outset Med | 0.0 | $39k | 10k | 3.85 | |
| Cero Therapeutics Holdings Class A Com | 0.0 | $3.9k | 13k | 0.30 |
